Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Completed · Phase 1/Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib and trastuzumab with docetaxel may kill more tumor cells. PURPOSE: This phase I/II trial is studying the best dose of docetaxel when given together with gefitinib and trastuzumab in treating patients with metastatic breast cancer.

Key facts

Study ID

NCT00086957

Run by

City of Hope Medical Center

People needed

31

Starts

2004-01-01

Expected to finish

2015-08-01

Last updated by the study team

2017-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Tower Cancer Research Foundation — Beverly Hills, California, United States
• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• Hematology Oncology Consultants-Hemet — Hemet, California, United States
• Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center — Long Beach, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• City of Hope Medical Group — Pasadena, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.